Abstract Introduction: Acquired hemophilia A (AHA) is a rare autoimmune hemorrhagic disorder characterized by neutralizing autoantibodies against coagulation factor VIII (FVIII). First-line immunosuppressive therapy with corticosteroids with or without rituximab achieves complete remission (CR) in 60-80% of patients; however, relapse occurs in approximately 15-33% of cases after treatment cessation.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile